Effects of alpha lipoic acid on iron overload, lipid profile and oxidative stress indices in β‐thalassemia major patients: A cross‐over randomised controlled clinical trial
| Autor: | Mohammad Reza Golpayegani, Jalal Moloudi, Laya Rezavand, Khadijeh Jamshidi, Zeynab Iraji, Seyed Mostafa Nachvak, Elham Sharifi-Zahabi, Sahar Asiaei, Hadi Abdollahzad |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Iron Overload Alpha-Lipoic Acid 030204 cardiovascular system & hematology Placebo medicine.disease_cause Antioxidants law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans 030212 general & internal medicine Thioctic Acid medicine.diagnostic_test business.industry beta-Thalassemia General Medicine Malondialdehyde Clinical trial Oxidative Stress Endocrinology chemistry Female lipids (amino acids peptides and proteins) Lipid profile business β thalassemia major Oxidative stress |
| Zdroj: | International Journal of Clinical Practice. 75 |
| ISSN: | 1742-1241 1368-5031 |
| DOI: | 10.1111/ijcp.14062 |
| Popis: | Aims β-Thalassemia major (β-TM) is associated with iron overload, abnormal lipid levels and oxidative stress. Alpha lipoic acid (ALA) showed anti-oxidant and iron chelating properties, but its effect in β-TM patients is unclear. We investigated the effects of ALA on iron levels, lipid profile and oxidative stress. Methods In this cross-over randomised clinical trial, 26 β-TM patients were assigned to receive 600 mg/d ALA or placebo (corn starch), for 8 weeks with a 21-days washout period. Serum ferritin, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C, total antioxidant capacity, malondialdehyde (MDA) and MDA/LDL-C were assessed at baseline and the end of each intervention phase. Results Twenty-two patients completed the study. Serum ferritin (P = .004), MDA (P = .025) and MDA/LDL-C ratio (P =.002) were decreased and HDL-C (P =.035) increased significantly during ALA consumption. In comparison with placebo, ALA decreased the serum ferritin significantly (P = .02). Also, the changes in serum ferritin between ALA and placebo (-123.1 ± 40.0 vs -34.3 ± 21.0, P =.03) was significant in women subgroup. ALA had no significant effects on the other biomarkers. Conclusion The results of this study indicated that supplementation with 600 mg/d ALA may decrease serum ferritin in β-TM. Further studies are needed to confirm the findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|